| 12.84 0.47 (3.8%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.16 | 1-year : | 17.7 |
| Resists | First : | 12.97 | Second : | 15.16 |
| Pivot price | 12.02 |
|||
| Supports | First : | 11.18 |
Second : | 10.06 |
| MAs | MA(5) : | 12.52 |
MA(20) : | 11.85 |
| MA(100) : | 9.76 |
MA(250) : | 11.75  |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 79 |
D(3) : | 76.2 |
| RSI | RSI(14): 70.3 |
|||
| 52-week | High : | 18.97 | Low : | 6.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RCUS ] has closed below upper band by 7.3%. Bollinger Bands are 13.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.87 - 12.93 | 12.93 - 12.99 |
| Low: | 12.01 - 12.08 | 12.08 - 12.14 |
| Close: | 12.73 - 12.84 | 12.84 - 12.94 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Wed, 24 Sep 2025
Cancer-focused Arcus Biosciences Awards 14,650 Combined Equity Grants Under Inducement Plan - Stock Titan
Mon, 15 Sep 2025
Arcus Biosciences, Inc. $RCUS Shares Purchased by Woodline Partners LP - MarketBeat
Sat, 13 Sep 2025
Arcus Biosciences (NYSE:RCUS) Stock Price Down 8% - Should You Sell? - MarketBeat
Mon, 08 Sep 2025
Arcus Biosciences Inc (RCUS) Announces Equity Awards for New Emp - GuruFocus
Sat, 06 Sep 2025
There's No Escaping Arcus Biosciences, Inc.'s (NYSE:RCUS) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Wed, 20 Aug 2025
Clinical-Stage Biotech Arcus Lines Up Citi, Morgan Stanley, and H.C. Wainwright September Conferences - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 106 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 34.7 (%) |
| Held by Institutions | 67.5 (%) |
| Shares Short | 9,830 (K) |
| Shares Short P.Month | 8,970 (K) |
| EPS | -3.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.15 |
| Profit Margin | -113.8 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | -50.4 % |
| Qtrly Rev. Growth | 310.2 % |
| Gross Profit (p.s.) | -2.1 |
| Sales Per Share | 2.46 |
| EBITDA (p.s.) | -3.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -339 (M) |
| Levered Free Cash Flow | -113 (M) |
| PE Ratio | -4.09 |
| PEG Ratio | 0 |
| Price to Book value | 2.48 |
| Price to Sales | 5.21 |
| Price to Cash Flow | -4.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|